Denali Therapeutics Inc. (NASDAQ:DNLI) Receives $33.71 Consensus Target Price from Analysts

Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) has been given an average recommendation of "Buy" by the seventeen ratings firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, fourteen have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $33.71.

Several research analysts have recently commented on DNLI shares. Cantor Fitzgerald raised Denali Therapeutics from a "neutral" rating to an "overweight" rating in a report on Thursday, April 10th. HC Wainwright reduced their target price on Denali Therapeutics from $80.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. William Blair raised Denali Therapeutics to a "strong-buy" rating in a report on Thursday, April 24th. Wedbush reduced their target price on Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Finally, Bank of America reduced their target price on Denali Therapeutics from $28.00 to $27.00 and set a "buy" rating on the stock in a report on Monday, May 19th.

Institutional Trading of Denali Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. raised its position in shares of Denali Therapeutics by 7.6% during the 4th quarter. Vanguard Group Inc. now owns 12,021,230 shares of the company's stock valued at $244,993,000 after acquiring an additional 843,996 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Denali Therapeutics by 15.9% during the 1st quarter. Wellington Management Group LLP now owns 11,409,598 shares of the company's stock valued at $155,113,000 after acquiring an additional 1,561,647 shares during the last quarter. FMR LLC raised its position in shares of Denali Therapeutics by 2.4% during the 4th quarter. FMR LLC now owns 8,019,746 shares of the company's stock valued at $163,442,000 after acquiring an additional 188,368 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Denali Therapeutics by 88.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,766,916 shares of the company's stock valued at $91,996,000 after acquiring an additional 3,184,042 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its position in shares of Denali Therapeutics by 42.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,367,234 shares of the company's stock valued at $59,373,000 after acquiring an additional 1,308,619 shares during the last quarter. Institutional investors own 92.92% of the company's stock.

Denali Therapeutics Stock Performance

Shares of DNLI stock traded down $0.44 during trading hours on Friday, hitting $14.25. The company had a trading volume of 1,158,196 shares, compared to its average volume of 1,135,187. Denali Therapeutics has a 12 month low of $10.57 and a 12 month high of $33.33. The firm has a market capitalization of $2.07 billion, a price-to-earnings ratio of -5.34 and a beta of 1.33. The firm's fifty day moving average is $14.38 and its 200 day moving average is $16.71.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.07). During the same period last year, the business earned ($0.68) earnings per share. On average, sell-side analysts expect that Denali Therapeutics will post -2.71 EPS for the current fiscal year.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.